Compare MMI & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMI | EVMN |
|---|---|---|
| Founded | 1971 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 892.4M |
| IPO Year | 2013 | N/A |
| Metric | MMI | EVMN |
|---|---|---|
| Price | $25.41 | $24.55 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $28.00 | ★ $43.29 |
| AVG Volume (30 Days) | 281.9K | ★ 310.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | ★ 84.38 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $719,700,000.00 | N/A |
| Revenue This Year | $14.04 | N/A |
| Revenue Next Year | $11.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.43 | $13.89 |
| 52 Week High | $36.70 | $33.20 |
| Indicator | MMI | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 50.06 |
| Support Level | $24.89 | $15.25 |
| Resistance Level | $27.32 | $33.20 |
| Average True Range (ATR) | 0.79 | 2.04 |
| MACD | -0.09 | -0.39 |
| Stochastic Oscillator | 8.99 | 51.55 |
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.